L.E.K. Consulting’s Inaugural Clinical and eClinical Pharma Services Survey

Insight Exchange by L.E.K. Consulting

Patients and sites that recruit and enroll patients change how trials are executed. Year after year, R&D costs incurred by biopharmaceutical companies to bring new therapies to the market are skyrocketing.

There is also a lack of appropriate racial representation among study participants. As clinical trial sponsors fail to reach their recruitment targets, these dynamics have led to a greater reliance on clinical trial partnerships for execution.

With this said, in this episode we'll clarify how sites and patients are changing the way trials are executed and how the necessary changes bring growth to the market.

We’re super excited to bring in Matt Wheeler and Ian Tzeng, both Managing Directors in L.E.K. Consulting’s Boston Office, to share their thoughts. They will be today’s speakers.

Connect with our experts on LinkedIn:

Matt Wheeler: https://www.linkedin.com/in/wheelermatthew/

Ian Tzeng: https://www.linkedin.com/in/iantzeng/

Visit L.E.K. Consulting at https://www.lek.com/